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The role of metals in the pathophysiology of Alzheimer’s disease (AD) has gained considerable support in recent years, with both
in vitro and in vivo data demonstrating that a mis-metabolism of metal ions, such as copper and zinc, may aﬀect various cellular
cascades that ultimately leads to the development and/or potentiation of AD. In this paper, we will provide an overview of the
preclinical and clinical literature that specifically relates to attempts to aﬀect the AD cascade by the modulation of brain copper
levels. We will also detail our own novel animal data, where we treated APP/PS1 (7-8 months old) mice with either high copper
(20 ppm in the drinking water), high cholesterol (2% supplement in the food) or a combination of both and then assessed β-
amyloid (Aβ) burden (soluble and insoluble Aβ), APP levels and behavioural performance in the Morris water maze. These data
support an interaction between copper/cholesterol and both Aβ and APP and further highlight the potential role of metal ion
dyshomeostasis in AD.
1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that results in the accumulation and aggregation
of key proteins within the brain that are believed to drive
the symptomatic presentation and pathological progression
of the disease. The underlying cause of AD has yet to
be elucidated however, there is an increasing burden of
proof on the role of metal dysregulation in the pathogenesis
of the disease. Other papers in this special edition will
detail the proposed role of copper in the generation and
aggregation of key AD-related proteins. In this paper, we
will review the preclinical and clinical trial data related to
attempts to aﬀect the AD cascade by the modulation of
brain copper levels. In addition, we will also present our own
novel data on long-term copper administration to APP/PS1
transgenic mice (one of the more widely used mouse models
of AD).
2. Therapeutic Intervention Studies
In this section, we will outline the various animal and human
trials that have been conducted that are specifically directed
at a modulation of copper. There are a number of additional
studies that will not be discussed, as these assess the eﬀect
of therapeutics that may alter a diversity of metals such as
copper, zinc, and iron. Keys among these are our own studies
with themetal ionophore, PBT2, which has shown promising
eﬀects in a number of diﬀerent transgenic mouse models of
AD and also in a phase 2a human clinical trial [1–4]. Its
mechanism of action is believed to rely on a normalisation
of metal ion (primarily copper and zinc) homeostasis within
the brain, which subsequently aﬀects a variety of cellular
cascades that, among other activities, serve to facilitate the
disaggregation and clearance of beta-amyloid (the principle
component of the amyloid plaques that characterises the
neuropathology of AD) and also maintains synaptic health
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and cognition. While these studies are of great value and
have provided impressive data to support this avenue of
investigation into the treatment of AD, their mechanisms of
action are complex and may not necessarily result from an
eﬀect on copper alone.
3. Preclinical Studies
Utilising the APP23 [B6-Tg(Thy1APP)23SdZ] mouse line,
Bayer and colleagues [5] treated aged animals (12 months
old) with deionized water containing either sucrose or a
combination of sucrose and copper sulfate (250 ppm). This
copper sulfate treatment, which lasted for three months,
was suﬃcient to elevate copper levels in the APP23 mice
(∼25% increase), thereby remedying the homeostatic copper
deficit present in this transgenic mouse line. The net eﬀect
on amyloid burden was a shift to decreased levels of both
PBS-soluble Aβ1-40 and 1-42 in male transgenic mice
only. Likewise, formic-acid-soluble amyloid burden was only
lower in the male animals treated with copper sulfate, while
histological amyloid load was decreased in both the male and
female transgenic mice treated with copper sulfate. These
data are consistent with our own findings, as reported here.
Utilising APP/PS1 mice (B6C3-Tg(APPswe, PSEN1dE9)
85Dbo/J on a B6C3 background (stock#004462, The Jackson
Laboratory); 7-8 months of age at the start of the trial; ani-
mals develop plaques around 4 months of age), we assessed
the eﬀect of either copper supplementation in the drinking
water (20 ppm in de-ionised water; n = 7), cholesterol
supplementation in the food (2% cholesterol in regular
rodent chow, provided by Specialty Feeds, Western Australia;
n = 6) or a combination of both (n = 4) on the levels of
brain amyloid (control animals received regular rodent chow
and regular deionised water; n = 5). Treatment was for a
period of 16 weeks and during the week prior to culling the
animals were assessed for spatial learning and memory in
the Morris water maze. In this task, animals were subject to
six consecutive days of learning trials (4 trials/day/mouse, 90
seconds/trial with a random quadrant entry and a 15 minute
inter-trial interval) and one recall task on the seventh day
(submerged platform removed from the pool, one 90 second
swimming trial/mouse). We have previously published these
techniques [3, 6, 7]. The animals were culled the day after
the recall task and the tissues collected (trans-cardial PBS-
perfusion followed by removal of the brain, which was
immediately dissected into two hemispheres, frozen on dry
ice and stored at −80◦C prior to analysis). Utilising an
in-house antibody (WO2), targeted against residues 5–8
of the human Aβ sequence that detects both full-length
monomeric Aβ as well as APP species, as well as a commercial
Aβ antibody (4G8, residues 17–21) that detects full-length
human Aβ, we assessed Aβ burden by western blot. We have
previously published these analytical methods [3, 4, 7] and
western blot assessments of Aβ have previously been shown
to detect the largest “pool” of this peptide in human samples
[8]. Our data (Figure 1) demonstrate similar trends for the
eﬀect of the individual treatments, with both the elevated
copper and the elevated cholesterol diets causing a trend to
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Figure 1: Assessment of Aβ burden in APP/PS1 mice by Western
blot. Total hemisphere homogenates (sonicated in PBS followed by
centrifugation at 100,000×g for 30 minutes at 4◦C and subsequent
isolation of the soluble and insoluble fractions. The insoluble
fraction was resuspended in PBS prior to a BCA assay and
subsequent Western blot) were assessed for Aβ content using both
an in-house antibody (WO2) (a) and a commercial (4G8) (b)
antibody. A significant reduction in insoluble Aβwas seen with both
antibodies for the combined high copper and cholesterol treatment
group only, as compared to the Tg control group (Tg).
a decrease in Aβ load. In contrast, a study [9] in a diﬀerent
APP/PS1 model (PS1M146L mice crossed with APPK670N,
M671L mice; mice develop plaques at 2-3 months of age)
found a trend to an increase in plaque burden in copper-
supplemented animals (plaque volume (mm2) on distilled
water alone: 1.63 ± 0.05; on copper-treated distilled water:
1.84 ± 0.05; P = 0.06). This study utilised a diﬀerent start
date for treatment (11 weeks of age, corresponding to the
start of plaque formation), period of treatment (6 weeks),
dose of copper (0.12 ppm copper sulfate) and method of
quantitation (histological assessment of Aβ plaque volume
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Figure 2: Assessment of APP levels in APP/PS1 mice by Western
blot. There is a significant reduction in APP levels in the transgenic
mice that received both a high-copper and a high-cholesterol diet,
as compared to the Tg control group (Tg).
using the antibody, 10D5) than our own work reported here.
These variable experimental parameters are likely to account
for the diﬀerences in the outcomes observed in both studies.
The copper and cholesterol treatments utilised in our
paradigm also appear to be additive, in that there was a
significant and exaggerated decrease in Aβ in the Tg animals
that received both elevated copper and cholesterol in their
diet, as compared to the transgenic animals receiving the
control diet (ANOVA: P = 0.02 for WO2 pellet/insoluble
data, P = 0.007 for 4G8 pellet/insoluble data). This eﬀect was
consistent across assays with both the in-house (Figure 1(a))
and the commercial (Figure 1(b)) Aβ antibody. These data
suggest an interaction of both copper and cholesterol on
Aβ metabolism in this transgenic mouse model of AD.
Analysis of APP levels (Figure 2) demonstrated that this
reduction in Aβ is likely a function of a direct eﬀect on
APP, whose protein expression profile closely paralleled that
found for Aβ, with a significant reduction in APP in the
animals that received the combined high cholesterol and
high copper diet (ANOVA: P = 0.0003). There was no
significant eﬀect of either the copper treatment (ANOVA:
P = 0.09) or the cholesterol treatment (ANOVA: P = 0.08)
on APP levels, although a trend to decrease was observed
with both. Despite these changes in Aβ levels, there were no
significant eﬀects observed in the performance of animals in
the Morris water maze task (Figure 3). Repeated measures
ANOVA across the six days of learning trials demonstrated
a trend to an overall diﬀerence between all treatment groups
(P = 0.07), with a significant treatment x day interaction
(P < 0.05). Post hoc analysis revealed a significant diﬀerence
across the trial when comparing the high-copper treatment
and the high-copper/cholesterol treatment groups (repeated
measures ANOVA: P = 0.02) and a trend to a diﬀerence
between the high-copper and the control transgenic groups
(repeatedmeasures ANOVA: P = 0.07). Taken together, these
data suggest that the decrease in Aβ resulting from a high-
copper diet may improve cognitive function, whereas the
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Figure 3: Assessment of spatial learning and memory in APP/PS1
mice in the Morris water maze. There is an overall trend for a
modulation of learning performance (a) on this task across the
various treatment groups. There was no significant eﬀect on recall
in the probe trial across the diﬀerent treatment groups (b).
combination of both a high-copper and a high-cholesterol
diet may negatively impact learning and memory, despite a
significant decrease in Aβ burden in those animals. This latter
observation, while apparently paradoxical, is consistent with
a community-based prospective study that reported that a
high-fat diet in conjunction with high-copper intake was
associated with a faster rate of cognitive decline in individuals
aged 65 years and older [10]. While the mechanisms
underlying this have not been pursued, it is likely that an
interaction between copper and cholesterol, particularly in
the aged brain, may be suﬃcient to generate unbuﬀered
reactive oxygen species which can contribute to neuronal
toxicity and ultimately to cognitive decline [11].
It is also important to note that the eﬀect of elevated
copper and/or cholesterol on a “normal” brain may diﬀer
markedly to that observed in a “diseased” brain (in which,
as is the case in the studies mentioned above, there is an
existing homeostatic deficit in copper levels in the brain).
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This is apparent from a number of studies where the
administration of copper and cholesterol to both rabbits [12]
and outbred mice [13] resulted in the accumulation of Aβ
and an impairment in various learning/memory tasks.
Thus, more detailed mechanistic investigations into the
eﬀect of copper and cholesterol on pathways related both
to Aβ metabolism and to cognitive function in both the
wildtype and the APP transgenic mouse are required in order
to reconcile the diﬀerences in these studies.
Following this same principle of elevating copper levels
to try and modulate the AD cascade, Phinney and col-
leagues utilised a genetic approach to achieve this goal [14].
They crossed TgCRND8 mice (a common AD transgenic
mouse line that shows a very rapid accumulation of Aβ
plaques) with txJ mice that harbour an autosomal recessive
mutation in the gene encoding the copper transport pro-
tein, CuATPase7b. The resulting animals (harbouring both
mutant human APP and also homozygous for the ATPase7b
mutation) had elevated brain copper levels, and the net eﬀect
on amyloid burden was similar to that shown in the two
studies above, with a decrease in the total brain levels of both
soluble- and formic-acid-extractable Aβ (assessed by ELISA)
and a significant reduction in the number of histologically
identified dense-cored plaques.
The modulation of brain copper levels, therefore, is
suﬃcient to alter the normal generation and metabolism
of Aβ in transgenic mouse models of AD. This hypothesis
has been further tested in a number of studies that have
pharmacologically manipulated copper levels in the brains of
APP transgenic mice.
The copper chelator pyrrolidine dithiocarbamate, for
example, was given chronically in the drinking water
(20mg/kg, 7 months) to APP/PS1 mice [15] and resulted
in a significant increase in brain copper levels, no signif-
icant change to amyloid burden, but did improve spatial
memory. In contrast, Crouch and colleagues [16] utilised
the copper bis(thiosemicarbazone) complex, CuII(gtsm),
which elevates cellular copper concentrations and activates
various signalling pathways relevant to amyloid metabolism.
When administered to APP/PS1 animals for 15 weeks
(10mg/kg/day), there was a significant decrease in PBS-
insoluble amyloid, which appeared to be largely driven by a
decrease in Aβ trimer species, and a parallel improvement in
performance in the Y-maze memory task.
Thus, these preclinical studies suggest that the modula-
tion of brain copper levels may be suﬃcient to impact the
normal pathogenesis of AD. The translation of this work to
human studies, however, has not shown the same potential
eﬃcacy of this therapeutic approach.
4. Clinical Studies
In the first study of its kind, Squitti and colleagues
[17] assessed the eﬀect of the copper-chelating agent, D-
penicillamine, (n = 17, 600mg per day for 6 months;
n = 17 placebo) in a small pilot study in AD patients. A
number of cognitive tests were used to assess the eﬀect of
the compound, including the Mental Deterioration Battery,
MMSE, NeuroPsychiatric Inventory, Geriatric Depression
Scale, and the Gottfries Brane Steen scale. While no signif-
icant cognitive eﬀects were observed, the placebo-treatment
group did not decline as expected, and this precluded any
conclusions being drawn on the eﬃcacy of D-penicillamine
on cognition (this lack of expected decline in placebo groups
has become a recurrent problem in AD trials). Despite this,
the data did suggest that there may have been an eﬀect
on a number of the biochemical parameters examined. The
authors concluded that larger patient numbers were required
to further elucidate the potential eﬃcacy of this approach for
the treatment of AD.
A more recent clinical trial involved oral copper sup-
plementation in a small cohort of AD patients [18, 19].
Individuals received either placebo (n = 33) or oral
copper orotate (n = 35; equivalent to 8mg copper per
day) for twelve months. The endpoints that were examined
included various CSF Aβ species (1-37, 1-38, 1-39, 1-40,
and 1-42 species), tau and phospho-tau (thr181) levels and
cognitive function, assessed using the Alzheimer’s Disease
Assessment Scale (ADAS-cog) and the minimental state
examination (MMSE). The only biomarker that changed
was Aβ1-42 levels, which decreased less (10% drop) in
the copper-supplementation group over the course of the
study, as compared to the placebo group (30% drop). All
other biomarkers and the cognitive scores were unchanged
between groups. The implications of the eﬀect seen on CSF
amyloid burden are unclear, and the authors concluded that
the copper supplementation had no eﬀect on the progression
of the AD phenotype.
5. Conclusions
These data highlight the diﬃculty in translating basic bench
science into eﬀective therapeutics. While it is clear that there
is a dyshomeostasis in copper levels in the AD brain that
may contribute to the pathogenesis of AD (both through a
disruption to normal copper-dependent pathways and also
via an eﬀect of copper on the aggregation and toxicity of
amyloid and formation of plaques) and that in vivo models
support the use of compounds that are able to modulate
copper levels as being eﬀective at interfering in the normal
AD cascades, testing these notions in a human population
have thus far been lacking. A definitive understanding of the
mechanisms of action and potential interactions of copper in
the AD brain are also lacking and are clearly complex. Metals
such as copper, for example, are very tightly regulated, and in
situations where there is a mismetabolism of copper, a simple
dietary supplement is unlikely to change this mismetabolism
and may not result in a restoration of cellular copper
homeostasis. The “unregulated” delivery of copper to the AD
brain may, for example, result in a number of consequences:
it may potentiate the aggregation and accumulation of β-
amyloid deposits (which arguably may represent either a
toxic or a protective phenomenon, depending on ones belief
about the role of and interaction between soluble oligomers
and insoluble Aβ plaques in the pathogenesis of AD); it
may aggravate oxidative pathways to generate toxic ROS or
also have other negative cellular eﬀects; it may also activate
a number of intracellular copper-dependent pathways that
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mediate an improvement in multiple aspects of the patho-
physiology of AD, including facilitating the degradation of
Aβ and reducing the abnormal phosphorylation of tau (as
has been shownwhen using amore targeted pharmacological
approach for the normalisation of copper homeostasis, such
as CuII(gtsm) reviewed in [20]). It is clear, therefore, that
attempting to modulate homeostatic systems is fraught with
diﬃculties and will require sophisticated approaches to the
targeted restoration of metal levels within the brain to ensure
that the required outcomes are achieved in the absence of any
toxicity. A greater burden of proof, and the identification of
a candidate compound, is required to help move this avenue
of research forward into robust human clinical trials.
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